Literature DB >> 31357774

[Guidelines for the diagnosis and treatment of liver fibrosis with integrated traditional Chinese and Western medicine (2019 edition)].

.   

Abstract

In 2006, the Hepatology Committee, Chinese Association of the Integration of Traditional and Western Medicine issued the "Guidelines for the Prevention and Treatment of Liver Fibrosis with Integrated Traditional Chinese and Western Medicine" . In recent years, in the field of modern medicine and integrated Chinese and Western medicine, the basic and clinical research into chronic liver disease has made rapid progress, and accumulated new evidence for the prevention and treatment of liver fibrosis. Therefore, in order to meet the clinical needs, experts of integrated traditional Chinese and Western medicine of liver diseases were united to revise the previous guidelines in order to help physicians make correct and reasonable decisions in the diagnosis and treatment of liver fibrosis.

Entities:  

Keywords:  Diagnosis; Guideline; Hepatic fibrosis; Integrated traditional and western medicine; Therapy

Mesh:

Year:  2019        PMID: 31357774     DOI: 10.3760/cma.j.issn.1007-3418.2019.07.005

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  4 in total

1.  The Role of GLI in the Regulation of Hepatic Epithelial-Mesenchymal Transition in Biliary Atresia.

Authors:  Pu Siyu; Wang Junxiang; Wang Qi; Zhang Yimao; Jin Shuguang
Journal:  Front Pediatr       Date:  2022-05-26       Impact factor: 3.569

2.  Identifying the Mechanism of Polygoni Cuspidati Rhizoma et Radix in Treating Acute Liver Failure Based on Network Pharmacology and Molecular Docking.

Authors:  Jing Hong; Jie Ding; Han-Han Hong; Xiao-Wan Xu; Bo Pan; Yi Ruan; Xiao-Feng Zhai
Journal:  Gastroenterol Res Pract       Date:  2022-04-08       Impact factor: 1.919

3.  Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: Protocol of systematic review and meta-analysis.

Authors:  Tianyao Zhang; Yu Yang; Baojia Wang; Xiuli Zheng; Long Wang; Xianrong Feng; Guiyu Li; Jinyu Shi; Ning Cao
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

4.  Development of a novel anti-liver fibrosis formula with luteolin, licochalcone A, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis.

Authors:  Yuan Zhou; Rong Wu; Fei-Fei Cai; Wen-Jun Zhou; Yi-Yu Lu; Hui Zhang; Qi-Long Chen; Ming-Yu Sun; Shi-Bing Su
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.